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Abstract
Introduction: The Randomized Aldactone Evaluation Study (RALES) randomized 822 patients to
receive 25 mg spironolactone daily and 841 to receive placebo. The primary endpoint was death from
all causes. Randomization began on March 24, 1995; recruitment was completed on December 31,
1996; follow-up was scheduled to continue through December 31, 1999. Evidence of a sizeable
benefit on mortality emerged early in the RALES. The RALES data safety monitoring board (DSMB),
which met semiannually throughout the trial, used a prespecified statistical guideline to recommend
stopping for efficacy. At the DSMB’s request, its meetings were preceded by an ‘endpoint sweep’, that
is, a census of all participants to confirm their vital status.
Methods: We used computer simulation to evaluate the effect of the sweeps.
Results: The sweeps led to an estimated 5 to 8% increase in the number of reported deaths at the
fourth and fifth interim analyses. The data crossed the statistical boundary at the fifth interim analysis. If
investigators had reported all deaths within the protocol-required 24-h window, the DSMB might have
recommended stopping after the fourth interim analysis.
Discussion: Although endpoint sweeps can cause practical problems at the clinical centers, sweeps
are very useful if the intervals between patient visits or contact are long or if endpoints require
adjudication by committee, reading center, or central laboratory.
Conclusion: We recommend that trials with interim analyses institute active reporting of the primary
endpoints and endpoint sweeps.
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Introduction
In randomized multicenter clinical trials monitored by an
independent Data and Safety Monitoring Board (DSMB)
charged with periodic evaluation of safety and efficacy, the
data available for review typically include fewer events
than have actually occurred when the database is closed.
The discrepancies arise from either a failure of the investi-
gators to report events soon after they occur or a failure of
the adjudication committees to classify events quickly.
This paper deals with an example of delays in reporting.
Many DSMBs prefer to review timely and relatively complete,
but unaudited, data rather than fully audited, incomplete
data, because delays in reporting endpoints may lead to
unacceptable tardiness in identifying effects of therapy [1].
Some authors [2] contend that in well-run trials, late report-
ing occurs only infrequently. However, our experience indi-
cates that even well-conducted long-term double-blind
multicenter trials, particularly ones conducted internationally,
often report many endpoints weeks or even months after
they occur. Late reporting is common even when death is the
primary endpoint. This problem leads to serious uncertainty
in interim analysis if the follow-up is not equally intense in
each of the various treatment arms. Because late reporting of
the primary endpoint can distort the estimated effect of
therapy, some clinical trialists perform an ‘endpoint sweep’,
that is, a census of all participants to confirm the status of
the primary endpoint, prior to each DSMB meeting [3]. Such
sweeps are especially useful if the intervals between patient
visits or contact are long or if endpoints require adjudication
by committee, reading center, or central laboratory.
The Randomized Aldactone Evaluation Study (RALES) [4],
a 195-center double-blind randomized clinical trial, ran-
domized 822 patients to receive 25 mg spironolactone
daily and 841 to receive placebo. The primary endpoint
was death from all causes. Scheduled length of follow-up
ranged between 3 and 4.5 years. The DSMB for the
RALES met twice yearly to review safety and efficacy. Evi-
dence of a sizeable benefit on mortality emerged early in
the trial (see Table 1, Look no.1). The protocol specified
that the investigator should report a death within 24 h after
its occurrence. Because the interval between protocol-
specified visits was every 3 months through 1 year of
study follow-up and every 6 months thereafter, the DSMB
suspected that there was a delay in reporting deaths. It
therefore asked the sponsor to confirm the vital status of
participants 2 years after the first patient was randomized.
Consequently, the sponsor asked all investigators to
confirm the vital status of each of their participants on 31
December 1997 and again on 30 June 1998.
This paper describes the interim monitoring plan used in
the RALES and the conduct of the endpoint sweeps. We
show that these sweeps led to a 5 to 8% increase in
deaths reported during the trial.
Methods
The RALES investigators randomized 1663 people with
class III or IV heart failure on the scale of the New York
Heart Association (NYHA) to receive spironolactone or
placebo. Randomization began on 24 March 1995. Each
participant was followed from randomization until the
study’s common closing date, which was planned to be
December 31, 1999, but actually occurred on August 24,
1998. The study was designed with 80% power to detect a
17% reduction in mortality, assuming some noncompliance
with study medication and complete ascertainment of vital
status. The secondary endpoints were cardiac mortality,
hospitalization for cardiac causes, the composite of cardiac
death or cardiac hospitalization, and change in class of
heart failure on the NYHA scale. Pitt et al [4] describe the
protocol, the dosing scheme, and the results; here we focus
on the planning and execution of the interim analyses.
Protocol-defined visits occurred at weeks 0, 4, 8, and 12;
at months 3, 6, 9, and 12; and then every 6 months until
the common close of the study. Investigators were to
report deaths within 24 h of discovery. Originally, the trial
was to continue until 540 deaths had occurred in the
placebo group. The sponsor amended the protocol in
March 1996 to continue randomizing until reaching a
sample size of 2500 patients or until 31 December 1996,
whichever occurred sooner. This change implied that the
last patient randomized would be followed for 36 months
unless the trial stopped early.
The DSMB, which was composed of three cardiologists
(DJ, chair; J-P B, HK), a cardiovascular epidemiologist, (CF),
and a statistician (SP), met semiannually throughout the trial
to review data relating to safety and efficacy. Spironolac-
tone, which has been in use since 1960, has a well-known
adverse event profile. The most common adverse events are
gynecomastia and other feminizing symptoms in males. The
most serious expected adverse event associated with the
use of spironolactone is hyperkalemia, because the drug
acts as a potassium-sparing diuretic.
The board monitored mortality with a statistical guideline for
stopping based on a Lan–DeMets [5] use function and an
O’Brien–Fleming boundary [6] for efficacy at a two-sided α
level of 0.05. It did not specify a formal boundary for safety,
relying instead on its collective judgment to recommend
early termination if spironolactone showed a net adverse
effect. The board unblinded itself regarding the treatment
code on 24 August 1996, its first planned interim analysis.
At the board’s third interim analysis meeting, on 25 August
1997, the prespecified critical z-value for declaring effi-
cacy of the drug was 3.67 (two-sided P = 0.00024); the
observed relative risk was 0.80 with a z-value of 2.55
(two-sided P = 0.011), insufficient evidence to stop the
trial. The board members were concerned that some
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deaths might remain unreported, especially among the
patients who were lost to follow-up and those who had
not come to their 12-month visit. Given the strong trends
in the data and the consistent patterns observed across
subgroups of interest, the board suspected that the data
would cross the prespecified stopping boundary before
the planned end of the study. To avoid crossing the statis-
tical boundary with uncertainty remaining about the
number of unreported deaths, the board requested that
each investigator provide a census of vital status as of 31
December 1997. In order not to alert the sponsor or inves-
tigators that the data were showing a strong trend, the
board worded its request in terms of the need for a ‘stan-
dard two-year’ accounting of data. At the DSMB meeting
in March 1998, after the ‘sweep’, the Board announced it
found the process so valuable that it requested sweeps
prior to each subsequent meeting. Because the board rec-
ommended stopping early, the study had only one addi-
tional sweep of deaths.
We used computer stimulation to evaluate the effect of
the sweeps. We assumed that the patterns observed up
to August 1998 would have persisted throughout the
study and simulated 1000 replications of a RALES trial
under these assumptions.
Results
The RALES showed fewer deaths on spironolactone than on
placebo throughout the entire course of the study. The rela-
tive risk of mortality remained close to 0.80 (see Table 1).
At the fifth interim analysis, in August 1998, 620 deaths
were reported. Assuming the protocol-projected mortality
rates, 1080 deaths would be expected at the planned end
of the study, yielding an estimated ‘information time’ of
620/1080 or 0.57. The actual number of deaths that
would have occurred had the study continued to its
planned end was of course unknowable; therefore, the
statistical center (JP, JW) provided a range of projected
number of deaths to examine the results’ sensitivity to the
assumptions. The range, from 518 to 648, corresponded
to a range of critical z-values from 2.70 to 3.08. The
observed z-value of 3.75 was greater than the z-value for
any of the projected number of deaths. Therefore, even if
the projection of 1080 were incorrect, the data would
have crossed the formal statistical boundary for efficacy.
The DSMB recommended termination of the study on
24 August 1998, when a total of 620 deaths had been
reported: 351 in the placebo group and 269 in the
spironolactone group. The chair of the study and the
Available online http://cvm.controlled-trials.com/content/2/1/059
Table1
Randomized Aldactone Evaluation Study (RALES) comparing spironolactone to placebo: observed and projected number of
deaths and summary statistics at the interim analyses
Observed
Data Meeting Estimated z-value Observed 
Look cutoff date Placebo Treatment Relative information P 
no. (d-mo-y) (d-mo-y) deaths deaths risk time* Critical Observed (two-sided)
Interim analysis cut-offs with the sweeps as they occurred
1 09-8-96 24-8-96 70 52 0.76 0.12 6.38 1.58 0.11
2 10-3-97 17-3-97 136 109 0.83 0.24 4.43 1.69 0.092
3 14-8-97 25-8-97 224 175 0.80 0.34 3.67 2.55 0.011
4 26-3-98 30-3-98 304 241 0.81 0.48 3.04 3.02 0.0026
5 14-8-98 24-8-98 351 269 0.78 0.57 2.79 3.75 0.00018
Estimated interim analysis cutoffs without the sweeps†
4a 26-3-98 30-3-98 281 222 0.81 0.45 3.16 2.93 0.0034
(275–289) (214–228) (0.76–0.85) (2.33–3.69)
5a 14-8-98 24-8-98 333 256 0.79 0.55 2.81 3.59 0.00034
(325–341) (248–264) (0.74–0.83) (2.87–4.33)
Interim analysis cutoffs that would have occurred if we had known the true numbers and times of deaths
1b 09-8-96 24-8-96 81 59 0.75 0.14 5.88 1.80 0.072
2b 10-3-97 17-3-97 189 140 0.76 0.26 4.24 2.75 0.0060
3b 14-8-97 25-8-97 257 201 0.80 0.38 3.46 2.82 0.0048
4b 26-3-98 30-3-98 330 254 0.79 0.51 2.95 3.56 0.00038
5b 14-8-98 24-8-98 383 283 0.76 0.60 2.72 4.46 0.000008
This three-panel table shows (a) the data observed in the RALES trial at each of the five interim analyses; (b) simulated data for the fourth and fifth
interim analysis had the sweeps not occurred; and (c) the data that would have been observed had all the deaths been reported within 24 h of their
occurrence, as specified by the protocol. *No. of events that have occurred divided by the no. of events that will occur up to the planned end of the
trial. Because the number of events that will occur is unknown at the time of a DSMB meeting, one must estimate it on the basis of data observed
thus far and assumptions made about the future. †Observed values are median number of events (in 1000 simulated iterations of the trial), with
ranges shown in parentheses. The 1000 iterations of the simulation assuming neither sweep showed a probablility of 18% and 100% that the data
would have first crossed the prespecified stopping boundary at the fourth and fifth interim analyses, respectively. These numbers refer to looks 4a
and 5a (data not shown).
sponsor concurred with this recommendation. After
RALES ended, the investigators and sponsor reported an
additional 46 deaths that had occurred prior to midnight,
2 August 1998. If all deaths had been reported within the
24-h window required by the protocol, the DSMB might
have recommended stopping after the fourth interim analy-
sis, when the critical and observed z-values would have
been 2.95 and 3.56, respectively (see Table 1, Look no. 4b).
To assess how the sweep affected the interim analyses, we
assumed that the patterns observed up to August 1998
would have persisted throughout the study; that is, 80% of
those identified in the sweep would have been identified at
the subsequent interim analysis, another 10% two meet-
ings later, and the final 10% at the end of the study. We
simulated 1000 replications of a RALES trial under these
assumptions. Table 1 (Look nos 4a and 4b) shows the data
that would have been reported. Even without the sweeps,
the data were highly likely to have crossed the monitoring
boundary at the fifth interim analysis. In terms of decision-
making, therefore, the sweeps probably did not change the
behavior of the board. The sweeps did, however, lead to a
much more complete set of data to form the basis of the
decision and much more security, on the part of the DSMB,
that its decision was correct. In the RALES, the data
showed no evidence of differential delay according to treat-
ment or of a differential rate of events in the deaths
reported with a delay and those reported on time. Thus, the
final results showed essentially the same reduction in mor-
tality as the DSMB observed, but because of the larger
number of deaths, the final P-value was lower than that
observed at the interim analysis.
In the RALES, the sweeps led to sizeable increases in the
number of reported deaths, and hence in the statistical
power, at both the fourth and fifth interim analyses. At the
fourth interim analysis, the sweep led to an 8% increase in
the number of reported deaths (from an estimated 503 to
an observed 545). If the sweep had identified all deaths, the
increase would have been 16% (503 to 584). At the fifth
interim analysis, the increase in number of deaths observed
was about 5% (589 to 620), with a potential increase of
13% (589 to 666) if the sweeps had identified all deaths.
Discussion
Our experience in the RALES emphasizes three aspects
of data collection for interim analysis – the need to project
the total number of events in a trial of fixed duration, the
importance of timely collection of data regarding the
primary endpoint, and the practical difficulties of reporting
endpoints in trials with long-term follow-up. To project the
total number of deaths that would have occurred in the
RALES if the trial had continued to its planned end, we
augmented the assumptions in the protocol with ranges of
reasonable other assumptions. If crossing the statistical
boundary is sensitive to the estimated number of deaths
that would occur, then a DSMB should be uncomfortable
recommending stopping.
The DSMB for the RALES, recognizing the importance of
timely data, requested endpoint sweeps. The board was
initially concerned that its request for endpoint sweeps
would raise suspicion that it was positioning itself for early
stopping. After the study ended, the DSMB learned that
the process had in fact alerted neither the sponsor nor the
investigators to such a possibility. Indeed, those carrying
out the study felt burdened by the request for sweeps. The
sponsor and the sites would have found them easier to
perform if the operations manual had originally incorpo-
rated them. In the RALES, a monitor reviewed charts at
each clinical site. This procedure, though consistent with
the Good Clinical Practice guidelines of the International
Conference on Harmonisation (see http://www.ifpma.org/
ich5.html), is not consistent with rapid reporting of end-
points. We recommend that trials with interim analyses
institute active reporting of the primary endpoints and end-
point sweeps, along with DSMB meetings.
Continuous identification of endpoints that require inde-
pendent adjudication poses more problems for interim
analyses than does mortality. If the primary endpoint for
the RALES had included, say, hospitalization due to wors-
ening heart failure, endpoint sweeps would have been
much more difficult. The investigators reported many of
the hospitalizations many months after the study ended.
Trials with an adjudication committee charged with
assessing the primary endpoint and a DSMB charged with
interim analysis must incorporate methods for timely adju-
dication of endpoints in order for the DSMB to discharge
its responsibilities. The institution of formal interim analysis
must be accompanied by resources that allow rapid col-
lection of relevant data. While we strongly recommend
sweeps, we also recommend that the procedures of a trial
specifically describe the sweeps to help alleviate the prac-
tical problems of identifying the endpoint status of people
at times other than at their planned clinic visits.
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